Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:SGMT

Sagimet Biosciences Q3 2026 Earnings Date & Estimates

Sagimet Biosciences logo
$10.42 +0.86 (+9.00%)
Closing price 10/27/2026 04:00 PM Eastern
Extended Trading
$9.93 -0.49 (-4.75%)
As of 10/27/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sagimet Biosciences is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Sagimet Biosciences in Q3 2026

Sagimet Biosciences is expected to post earnings of -$0.25 per share on revenue of $167 thousand. In the same quarter a year earlier Sagimet Biosciences reported -$0.40 per share. Sagimet Biosciences last reported on August 11, 2026, posting -$0.26 per share and missing the -$0.2510 consensus estimate. Sagimet Biosciences has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.25
Expected Revenue
$167 thousand
Prior-Year EPS
-$0.40

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.26 (Missed by -$0.0090)
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Sagimet Biosciences Q3 2026 Earnings FAQ

Sagimet Biosciences (NASDAQ:SGMT) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Sagimet Biosciences' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Sagimet Biosciences to post earnings of -$0.25 per share for Q3 2026.

The consensus revenue estimate for Sagimet Biosciences is $167 thousand for Q3 2026.

Sagimet Biosciences Earnings Headlines

Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Revolution Medicines (RVMD)
October 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/8366183/analysts-offer-insights-on-healthcare-companies-sagimet-biosciences-inc-class-a-sgmt-and-revolution-medicines-rvmd/
Sagimet Biosciences Begins Pivotal Phase 3 Study Of Denifanstat In Acne Patients
October 22, 2026  |  rttnews.comhttps://www.rttnews.com/3701924/sagimet-biosciences-begins-pivotal-phase-3-study-of-denifanstat-in-acne-patients.aspx
Yesterday's deadline changed everything
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
 |  Behind the Markets (Ad)
Sagimet Biosciences Doses First Patient in US Phase 3 Trial of Denifanstat to Treat Acne
October 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sagimet-biosciences-doses-first-patient-133029315.html
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386187/0/en/sagimet-biosciences-announces-first-patient-dosed-in-aurora-phase-3-u-s-clinical-trial-of-denifanstat-for-moderate-to-severe-acne.html
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
October 21, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4955859-sagimet-biosciences-stock-us-acne-trial-replication-exercise-not-discovery-bet
See More Sagimet Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sagimet Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sagimet Biosciences and other key companies, straight to your email.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ:SGMT), Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company developing therapies that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company is focused on using FASN inhibition to address metabolic, inflammatory and oncological diseases for which additional treatment options are needed.

Sagimet’s lead investigational product is denifanstat, an orally administered, selective FASN inhibitor formerly known as TVB-2640. The company has primarily advanced denifanstat as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease associated with liver inflammation and fibrosis. Denifanstat has also been evaluated in clinical research involving other diseases, including certain cancers and inflammatory conditions.

The company’s operations are centered on research, clinical development and regulatory advancement rather than commercialized products. Sagimet was formerly known as 3-V Biosciences and is based in San Mateo, California. Its programs are being developed for potential use in global markets, subject to successful clinical trials and regulatory approvals. Sujal Shah serves as president and chief executive officer.

View Sagimet Biosciences Profile
Earnings Tools